EGFR and non-small cell lung carcinoma: At American Society of Clinical Oncology (ASCO) 2021, the latest data from a phase I dose escalation/expansion trial including 39 patients with locally advanced or metastatic NSCLC with EGFR mutations who had experienced disease progression after EGFR-TKI therapy were presented.